Safe treatment of a patient with CML using dasatinib after prior retinal oedema due to imatinib.
Bajel
Ashish
A
Bassili
Saf
S
Seymour
John F
JF
D000328:Adult; D001549:Benzamides; D000069439:Dasatinib; D004487:Edema / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy*; D008297:Male; D010879:Piperazines / Q000009:adverse effects*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use*; D012164:Retinal Diseases / Q000139:chemically induced* / Q000188:drug therapy; D013844:Thiazoles / Q000627:therapeutic use*
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D000069439:Dasatinib